Kevin Krause
Corporate Officer/Principal bei AN2 THERAPEUTICS, INC.
Vermögen: 72 764 $ am 30.04.2024
Aktive Positionen von Kevin Krause
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AN2 THERAPEUTICS, INC. | Corporate Officer/Principal | 01.08.2021 | - |
Karriereverlauf von Kevin Krause
Ehemalige bekannte Positionen von Kevin Krause
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ACHAOGEN | Corporate Officer/Principal | 01.01.2015 | 01.06.2019 |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Corporate Officer/Principal | 01.08.2010 | 01.12.2014 |
Ausbildung von Kevin Krause
Haas School of Business | Masters Business Admin |
San Francisco State University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
Corporate Officer/Principal | 3 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AN2 THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Health Technology |
- Börse
- Insiders
- Kevin Krause
- Erfahrung